Reversible pisa syndrome induced by rivastigmine in a patient with early-onset Alzheimer disease

Chih Wei Hsu, Yu Chien Lee, Chun Yi Lee, Pao Yen Lin*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

9 Scopus citations

Abstract

Pisa syndrome (PS) is a state of dystonic muscle contraction with a marked truncal deviation to one side. It is an uncommon adverse effect of antipsychotic drugs, but is rarely reported in patients receiving acetylcholinesterase inhibitors, especially rivastigmine. We present a 57-year-old female patient with Alzheimer disease who began to develop symptoms of dementia at the age of 51 years. Shewas observed to have symptoms of PS after continuous use of rivastigmine (9mg/d) for nearly 2 years. The PS symptoms improved after the dose of rivastigminewas reduced but recurred when the dose was added back to 9 mg/d. Finally, after we decreased the dose to 4.5 mg/d, her PS symptoms were remitted. This report reminds us that clinicians need to be cautious about the risk of PS when prescribing rivastigmine in a patient with early-onset Alzheimer disease.

Original languageEnglish
Pages (from-to)147-148
Number of pages2
JournalClinical Neuropharmacology
Volume40
Issue number3
DOIs
StatePublished - 2017

Bibliographical note

Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

  • Acetylcholinesterase inhibitor
  • Distonia
  • Pisa syndrome
  • Rivastigmine

Fingerprint

Dive into the research topics of 'Reversible pisa syndrome induced by rivastigmine in a patient with early-onset Alzheimer disease'. Together they form a unique fingerprint.

Cite this